TSL Thinksmart Limited

RNS Number:1246M
Tissue Science Laboratories PLC
15 November 2006


For immediate release                                           15 November 2006

                        Tissue Science Laboratories PLC
                            ("TSL" or the "Company")

         Tissue Science Laboratories EGM approves #2.8 million Placing

Tissue Laboratories plc (AIM: TSL), the medical technology company specialising
in biologic tissue replacement and repair products, announces that at the
Extraordinary General Meeting ("EGM") of the Company held earlier today, all
resolutions put to shareholders were duly passed. Accordingly, authority has
been granted to the Directors to allot shares, and to disapply pre-emption
rights on the allotment of shares, pursuant to the Placing announced on 23
October 2006 ("Placing"). The Company has raised #2.8 million, gross of
expenses, in the Placing in response to feedback from investors that they would
like to provide the Company with additional working capital headroom, to
continue the development and expansion of the business.

The 5,090,910 new Ordinary Shares of 10 pence each in the Company to be issued
in the Placing at a price of 55 pence per share are expected to be admitted to
trading on AIM tomorrow, 16 November 2006.  Following admission of the new
Ordinary Shares to trading on AIM, there will be 34,601,657 Ordinary Shares in
the Company in issue.

Full details of the Placing are set out in the shareholder circular published on
23 October 2006.

                                     -Ends-

Enquiries:

Tissue Science Laboratories Plc                       01252 369603
Martin Hunt, Chief Executive                            
David Jennings, Finance Director


Nomura Code Securities Limited
Juliet Thompson                                       0207 7761204
Clare Terlouw                                         0207 7761205


Hogarth Partnership Limited                           0207 357 9477
James Longfield                                         
Sarah Richardson



Notes to Editors

Background on TSL

Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product, derived from porcine dermis, called Permacol(R)(R).
TSL has launched successfully different formulations of the product and built a
development pipeline that addresses the large and fast growing surgical implant
market. The Company floated in November 2001 and is listed on AIM (AIM: TSL).
TSL has a family of products based on the same core technology. Each product has
been adapted to make it suitable for use in different applications, including
urology/gynaecology, complex and recurrent hernia repair, shoulder rotator cuff
repair and head and face repair and reconstruction. The Company has signed
distribution agreements with CR Bard Inc (urology/gynaecology-worldwide), Zimmer
Inc (orthopaedic-worldwide) and Porex Surgical Inc (head & face-US and Canada).
Further variations of the sheet and injectable forms of Permacol(R)(R) are being
developed.

Background on Permacol(R)(R)

Permacol(R)(R) was developed at Dundee and Cambridge Universities over a 20-year
time period. The key to the Permacol(R)(R) concept lies in it collagen
technology which uses non-reconstituted porcine dermal collagen, very similar in
structure to human tissue. Non-collagenous material, except elastin, is removed
by the TSL manufacturing process. The remaining collagen, which retains its
original 3-D structural architecture, is stabilised by a patented cross-linking
process. The result is a non-reconstituted, non-allergenic, collagen implant
which is resistant to biodegradation, is recognised and accepted by the body,
and is able to provide a long-term support for the in-growth of new tissue and
its associated blood supply.





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
REGFGMMMZKRGVZM

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Giu 2024 a Lug 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2023 a Lug 2024